HomeCompareNPSKF vs JNJ

NPSKF vs JNJ: Dividend Comparison 2026

NPSKF yields 2.51% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 JNJ wins by $9.2K in total portfolio value· pulled ahead in Year 6
10 years
NPSKF
NPSKF
● Live price
2.51%
Share price
$7.93
Annual div
$0.20
5Y div CAGR
-20%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$21.1K
Annual income
$28.84
Full NPSKF calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — NPSKF vs JNJ

📍 JNJ pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNPSKFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NPSKF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NPSKF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NPSKF
Annual income on $10K today (after 15% tax)
$213.16/yr
After 10yr DRIP, annual income (after tax)
$24.51/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, JNJ beats the other by $3,961.48/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NPSKF + JNJ for your $10,000?

NPSKF: 50%JNJ: 50%
100% JNJ50/50100% NPSKF
Portfolio after 10yr
$25.7K
Annual income
$2,359.12/yr
Blended yield
9.19%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

NPSKF
No analyst data
Altman Z
2.1
Piotroski
7/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NPSKF buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNPSKFJNJ
Forward yield2.51%2.13%
Annual dividend / share$0.20$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-20%28%
Portfolio after 10y$21.1K$30.3K
Annual income after 10y$28.84$4,689.40
Total dividends collected$926.00$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NPSKF vs JNJ ($10,000, DRIP)

YearNPSKF PortfolioNPSKF Income/yrJNJ PortfolioJNJ Income/yrGap
1$10,901$200.63$10,592$272.30+$309.00NPSKF
2$11,827$163.51$11,289$357.73+$538.00NPSKF
3$12,788$132.64$12,123$472.89+$665.00NPSKF
4$13,790$107.23$13,141$629.86+$649.00NPSKF
5$14,842$86.45$14,408$846.81+$434.00NPSKF
6← crossover$15,950$69.57$16,021$1,151.60$71.00JNJ
7$17,123$55.90$18,122$1,588.22$999.00JNJ
8$18,366$44.86$20,930$2,228.20$2.6KJNJ
9$19,688$35.98$24,792$3,191.91$5.1KJNJ
10$21,095$28.84$30,274$4,689.40$9.2KJNJ

NPSKF vs JNJ: Complete Analysis 2026

NPSKFStock

NSK Ltd., together with its subsidiaries, manufactures and sells industrial machinery bearings, automotive products, and precision machinery and parts worldwide. Its products include ball bearings; roller bearings; bearing units; super precision bearings; bearings for steel industry, mining and construction, papermaking machines, and pumps and compressors; and bearings for special environments, including sanitary, corrosive, vacuum, clean, high-temperature, non-magnetic requirement, and dust-contaminated environments. The company also provides automotive products, which comprise chassis products, such as electric power steerings, steering column and intermediate shafts, and hub unit bearings; power train products comprising engine parts and electrical accessories; and drive train products consisting of automatic and manual transmission, products for motorcycles and all-terrain vehicles, half toroidal CVT POWERTOROS units, and differential gear and propeller shafts. In addition, it offers precision machine components, including ball screws, linear guides, monocarriers, XY tables, and spindles; and accessories, including ball screw support bearings, air bearings, and clean grease, as well as support units for heavy and light loads, machine tools, and small equipment. Further, the company provides megatorque motors; maintenance and repair services; design, development, sales, and maintenance services for computer systems and networks; and sells industrial machinery bearings and automotive components. It serves agriculture, automotive, cement, food processing machinery, industrial motor, gearbox, injection molding machine, machine tool, medical device, mining and construction, motorcycle, office equipment, palm oil, papermaking machinery, pump and compressor, railway, semiconductor, steel, sugar, and wind turbine industries. NSK Ltd. was founded in 1914 and is headquartered in Tokyo, Japan.

Full NPSKF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this NPSKF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NPSKF vs SCHDNPSKF vs JEPINPSKF vs ONPSKF vs KONPSKF vs MAINNPSKF vs ABBVNPSKF vs MRKNPSKF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.